Oxford, UK, 27th Sep 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the appointment of Richard Taylor to its Board of Directors.
Richard Taylor MA ACMA has been appointed as a Non-Executive Director to the Board of cancer drug development company Celleron Therapeutics, Oxford, UK. As Managing Director at GRE Investment Advisors, Hong Kong, Richard brings to Celleron Therapeutics, more than 30 years of investment banking experience in both the London and Asian markets. Richard was the former Head of Investment Banking, Corporate Finance and Capital Markets at CLSA Bank, Hong Kong, raising in excess of US$200b across the 200+ transactions he completed during his time there
Professor Nick La Thangue, Chief Executive Officer of Celleron Therapeutics, commented: “We are delighted that Richard is joining the Celleron Therapeutics Board of Directors. His depth of knowledge and wide experience of the Asian and global investment markets is unrivalled and will be of paramount importance as the company grows it global presence”.
Richard Taylor, MA ACMA commented: “I am delighted to join the board of Celleron Therapeutics. The Company is at a very exciting stage in the development of its oncology clinical assets and has already established a strong scientific connectivity with Asia. I hope that I can bring my Asian capital markets, corporate and investor relationships to further extend this connectivity”.
About Celleron Therapeutics Limited
Celleron Therapeutics is a biopharma advancing a clinical and pre-clinical pipeline of precision therapies for different cancer indications. The company is located on the Oxford Science Park, UK. Celleron Therapeutics has built a proprietary platform around epigenetic control and immune modulation, providing its drugs with a two-pronged attack on cancer. Celleron Therapeutics’ approach seeks to align the right drug with the right patient enabling a personalised approach to cancer therapy. Celleron Therapeutics’ focus is on those cancers where there is still an unmet need for long-term disease control. It is hoped that not only will patients volunteering for our clinical trials benefit directly, but the results from these studies will ultimately allow the general use of more effective, safer medicines. Our goal is not only to treat cancer but improve quality of life during therapy by reduction of side effects.
Celleron Therapeutics has global license partnerships with Astra Zeneca and Roche. The company secured investment in 2016 from a consortium of South Korean investors; and in 2020 span out an affiliate company, SynOx Therapeutics.For more information, please visit https://cellerontherapeutics.com